| 摘要 |
The present invention has found that inhibitors reducing the glycolytic flux can be used for treatment of neurodegenerative diseases such as Alzheimer's disease, Parkonson's disease and amyotrophic lateral sclerosis. In particular the invention provides constructs comprising siRNAs directed against PHD1 for the treatment of ALS and siRNA's directed against PFKFB3 for the treatment of neurodegenerative diseases. The invention also provides the use of a therapeutically effective amount of aza chalcones or a pharmaceutically acceptable salt thereof for the treatment of neurological diseases. |
